Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones

被引:54
|
作者
Wispelwey, B [1 ]
机构
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1086/428053
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review summarizes key data illustrating the clinical importance of pharmacodynamics, particularly among the fluoroquinolone family of antibacterials. Antibacterials are often divided into 2 groups - either time-dependent or concentration-dependent agents - on the basis of their mechanism of killing. Fluoroquinolones are concentration-dependent agents, and the parameter that correlates most closely with clinical and/or bacteriological success is the ratio of the area under plasma concentration curve (AUC) to the minimum inhibitory concentration ( MIC). The AUC: MIC threshold may vary by organism. For example, a ratio of at least 30 is often cited as optimal to achieve success against Streptococcus pneumoniae, whereas higher ratios ( > 100) are considered to be optimal for the treatment of infections due to gram-negative bacilli. Data are cited to suggest that the minimum ratio necessary to prevent the selection of resistant mutants may, in fact, be somewhat higher. Maximizing the AUC: MIC through the use of potent therapy may offer an opportunity to limit the development of resistance to fluoroquinolones.
引用
收藏
页码:S127 / S135
页数:9
相关论文
共 50 条
  • [1] Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones
    Wispelwey, B
    CLINICAL INFECTIOUS DISEASES, 2005, 40 : S439 - S447
  • [2] Pharmacokinetics and Pharmacodynamics of Fluoroquinolones
    John Turnidge
    Drugs, 1999, 58 : 29 - 36
  • [3] Pharmacokinetics and pharmacodynamics of fluoroquinolones
    Turnidge, J
    DRUGS, 1999, 58 (Suppl 2) : 29 - 36
  • [4] Pharmacokinetics and pharmacodynamics of fluoroquinolones
    Rodvold, KA
    Neuhauser, M
    PHARMACOTHERAPY, 2001, 21 (10): : 233S - 252S
  • [5] Pharmacokinetics and pharmacodynamics of newer fluoroquinolones
    Stein, GE
    CLINICAL INFECTIOUS DISEASES, 1996, 23 : S19 - S24
  • [6] Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
    Wise, R
    Honeybourne, D
    EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (01) : 221 - 229
  • [7] Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications
    Julie Autmizguine
    Jeffrey T. Guptill
    Michael Cohen-Wolkowiez
    Daniel K. Benjamin
    Edmund V. Capparelli
    Drugs, 2014, 74 : 891 - 909
  • [8] CLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF ZOLPIDEM - THERAPEUTIC IMPLICATIONS
    SALVA, P
    COSTA, J
    CLINICAL PHARMACOKINETICS, 1995, 29 (03) : 142 - 153
  • [9] Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications
    Autmizguine, Julie
    Guptill, Jeffrey T.
    Cohen-Wolkowiez, Michael
    Benjamin, Daniel K., Jr.
    Capparelli, Edmund V.
    DRUGS, 2014, 74 (08) : 891 - 909
  • [10] Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
    Chris Stockmann
    Jonathan E. Constance
    Jessica K. Roberts
    Jared Olson
    Elizabeth H. Doby
    Krow Ampofo
    Justin Stiers
    Michael G. Spigarelli
    Catherine M. T. Sherwin
    Clinical Pharmacokinetics, 2014, 53 : 429 - 454